deferasirox has been researched along with er-086526 in 1 studies
Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (er-086526) | Trials (er-086526) | Recent Studies (post-2010) (er-086526) |
---|---|---|---|---|---|
832 | 136 | 572 | 567 | 113 | 517 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Amano, R; Asano, Y; Fujita, H; Goto, W; Hirakawa, K; Kashiwagi, S; Morisaki, T; Ohira, M; Shibutani, M; Takada, K; Takahashi, K; Takashima, T; Tomita, S | 1 |
1 other study(ies) available for deferasirox and er-086526
Article | Year |
---|---|
Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
Topics: Animals; Antigens, CD; B7-H1 Antigen; Cadherins; Cell Cycle; Cell Line, Tumor; Deferasirox; Deferoxamine; Epithelial-Mesenchymal Transition; Female; Furans; Humans; Iron; Iron Chelating Agents; Iron Deficiencies; Ketones; Mice; Mice, Inbred BALB C; Mice, Nude; RNA, Messenger; RNA, Neoplasm; Triple Negative Breast Neoplasms; Tubulin Modulators; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |